linjc16/ctgov huggingface dataset:
Efficiency and Usability of the Iontophoretic Patch Feeligreen Diclofenac in Treating Acute Osteoarthritic Knee Pain

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the antalgic efficacity of Feeligreen® patch on osteoarthritic knee pain acute. This patch work by diffusion controlled by iontophoresis allowing an improvement of transdermal diffusion of active (Diclofenac).

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Device: Feeligreen patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with age above 70 years, Having a knee Arthritis (unilateral or bilateral) for at least 6 months, Pain intensity ≥ 40 mm on a visual analog scale (VAS) Lack of analgesic treatment or analgesic, Exclusion Criteria: Cognitive disorders : moderate to severe stage or not allowing an understanding of the VAS (as determined by the clinician) A history of chronic inflammatory rheumatic disease, Diagnosis of osteoarthritis of secondary origin, Non-steroidal anti-inflammatory medication within 7 days prior to inclusion, Diagnosis of severe hepatic and renal insufficiency, gastrointestinal bleeding, severe heart failure, Allergy to diclofenac or similar activity substances such as other NSAIDs, aspirin, excipients, Damaged skin

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients<br> | Device: Feeligreen patch<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity reduction of pain | Measured by Visual Analog Scale | 2 days |
Pharmacokinetics of Vancomycin in Adults Receiving ECMO

Study Overview
=================
Brief Summary
-----------------
Vancomycin is a drug that requires precise dosing and close monitoring to avoid drug toxicity. There is limited data on the change of vancomycin pharmacokinetics in patients who need extracorporeal membrane oxygenation (ECMO). This control trial is to understand: whether the pharmacokinetics of vancomycin is influenced by the use ECMO design the most appropriate dose of vancomycin in adult patients using ECMO.

Detailed Description
-----------------
Vancomycin is a drug that requires precise dosing and close monitoring to avoid drug toxicity. Oftentimes it is used in intensive care units (ICU) for patients who need a life-saving machine for heart and lung failure called extracorporeal membrane oxygenation (ECMO). There is limited data on the change of vancomycin pharmacokinetics in these patients. This is a control trial using ICU patients who need vancomycin but not ECMO as a control to understand: whether the pharmacokinetics of vancomycin is influenced by the use ECMO design the most appropriate dose of vancomycin in adult patients using ECMO. After the 4th dose of vancomycin, blood was drawn at appropriate time spots (1 mL each) to determine the time concentration curve and to calculate the pharmacokinetic parameters for 2 groups of patients to determine if there is any difference.

Official Title
-----------------
Pharmacokinetics and Posology of Vancomycin in Adults Receiving ECMO

Conditions
-----------------
Extracorporeal Membrane Oxygenation

Intervention / Treatment
-----------------
* Drug: vancomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 y/o receiving ECMO for study group without ECMO for control group (sex, age, creatinine clearance match with study group) Exclusion Criteria: severe burn (>30-40% BSA) receiving continuous renal replacement therapy or hemodialysis concurrently

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: vancomycin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pharmacokinetic parameters |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Extracorporeal Membrane Oxygenation, vancomycin
Review of Pain Management After Congenital Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
One of the main problems that faces children undergoing congenital cardiac surgery is posoperative pain management. PCAs (Patient Controlled Analgesia) and NCAs (Nurse Controlled Analgesia) are the main means of pain management here at NCH. In this study, the investigators will review the difference between different PCA and NCA modalities. Also, the investigators aim to find out if there are differences between age groups in terms of type of drug used, total drug used, side effects and length of use of the PCA or NCA.

Detailed Description
-----------------
All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA will be included. Data will be collected from the pain team database and charts review. Data will include; patient's age, weight, sex, procedure, pain scores and sedation score during the times of PCA and NCA use, side effects (respiratory depression, nausea, vomitting, pruritus, itching and other).In addition we will record the total days of PCA and NCA use. We will also look at the incidence of changes done in the PCA/NCA and drug itself. Identifying the ideal drug and dose based on the patient's age and procedure will allow us to take better care of our patients. Our patient population is peculiar in the fact that a big percentage of our patients are extubated in the Operating Room. For this reason, sedation and analgesia play an important role for our continued success in taking care of them.

Official Title
-----------------
Review of Pain Management After Congenital Cardiac Surgery

Conditions
-----------------
Postoperative Pain Management

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA. Exclusion Criteria: All patients that underwent congenital cardiac surgery from 2004 till 2010 and did not receive PCA or NCA for postoperative pain management.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Post congenital cardiac surgery pain management<br>All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congenital cardiac surgery, Postoperative pain management
HIV Physician's Survey

Study Overview
=================
Brief Summary
-----------------
This is a survey study to assess the variability in the current management of pregnancy, reproductive care and assisted reproductive technologies for HIV-positive individuals in Canada to estimate interest for further projects.

Official Title
-----------------
Canadian Health Care Providers' Attitudes of Pregnancy, Fertility Care, and Assisted Reproductive Technologies for HIV-Positive Individuals

Conditions
-----------------
HIV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any HIV health care provider Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, HIV providers, Infectious Disease, HIV and pregnancy
Low Grade Chondrosarcoma Versus Enchondroma

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to verify possible clinical and radiological findings with regard to distinguishing enchondroma from low grade chondrosarcoma of the long bones. In addition, this study presents the outcome of patients with enchondroma and low grade chondrosarcoma of the long bones who were treated with curettage (intralesional surgery).

Detailed Description
-----------------
The investigators retrospectively review the records of 65 patients with enchondroma and 37 patients with low grade chondrosarcoma of the limbs treated by curettage between 1988 and 2014 in a single Institution.

Official Title
-----------------
Low Grade Chondrosarcoma Versus Enchondroma: Challenges in Diagnosis and Management

Conditions
-----------------
Chondroma, Chondrosarcoma

Intervention / Treatment
-----------------
* Procedure: curettage (intralesional surgery)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chondroma or low grade chondrosarcoma of long bones Exclusion Criteria: chondroma or low grade chondrosarcoma of spine and pelvis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: curettage (intralesional surgery)|comparison of two different tumors treated by curettage|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local recurrence rate of patients with chondroma or low grade chondrosarcoma treated by curettage (intralesional surgery) |  | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bone tumors, chondroma, chondrosarcoma
A Registry Study on HIV-related Lymphoma

Study Overview
=================
Brief Summary
-----------------
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

Detailed Description
-----------------
To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.

Official Title
-----------------
Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group

Conditions
-----------------
AIDS Related Lymphoma, HIV Related Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma HIV-infection at time of lymphoma diagnosis Lymphoma diagnosis since 01.01.2010 Adult patients ≥ 18 years Written informed consent Exclusion Criteria: HIV-diagnosis > 3 months after the diagnosis of malignant lymphoma Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2-year overall survival (OS) | OS measured from the date of diagnosis to last follow-up or to death from any cause. | 2 years | 
| 2-year progression-free survival (PFS) | PFS calculated from the date of diagnosis to the time of progression, relapse, or death. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of relapse (IR) | Based on establised response criteria, e.g. Chesson et al. JCO 2014 | 5 years | 
| Non-relapse mortality (NRM) | Deaths unrelated to lymphoma | 5 years | 
| 5-year overall survival (OS) | OS measured from the date of diagnosis to last follow-up or to death from any cause. | 5 years | 
| 5-year progression-free survival (PFS) | PFS calculated from the date of diagnosis to the time of progression, relapse, or death. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malignant lymphoma, HIV-related lymphoma, HIV-associated Hodgkin lymphoma
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Study Overview
=================
Brief Summary
-----------------
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Detailed Description
-----------------
Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis. Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.

Official Title
-----------------
An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis

Conditions
-----------------
Scalp Psoriasis

Intervention / Treatment
-----------------
* Drug: DSXS topical product


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or non-pregnant, non-lactating females 12-17 years of age. Exclusion Criteria: Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DSXS topical product<br>treatment with DSXS once daily for 28 days | Drug: DSXS topical product<br>* treatment daily for 28 days<br>* Other names: Active;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With HPA Axis Suppression | Hypothalamic Pituitary Adrenal (HPA) Axis Response to stimulation | day 28 |
Short Intervention for Medication Overuse Headache (MOH) - Pilot

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is together with the BIMOH (NCT01314768) RCT study to evaluate whether training of GPs in the detection and treatment of medication overuse headache leads to improved care for these patients as compared to business as usual.

Detailed Description
-----------------
The present pilot study focuses on testing the logistics and the methodology of short intervention on a pilot group of GPs and their patients. Due to low recruitment and the pilot study focus on logistics and methodology, the study was changed to not include a control (business as usual) arm. The outcomes were evaluated as before - after data and qualitative comments on acceptability and utility of the method. Primary outcomes were changed to be the acceptability and utility (previously listed as secondary outcomes) while secondary outcomes were headache days and medication days (previously listed as primary).

Official Title
-----------------
Pilot Study of Short Intervention for Medication Overuse Headache in General Practice

Conditions
-----------------
Medication Overuse Headache

Intervention / Treatment
-----------------
* Behavioral: Trained counselling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with medication overuse headache Exclusion Criteria: Other complicating pain condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Trained counselling<br>Comparison of outcomes before intervention vs. 2 months after | Behavioral: Trained counselling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative comments of participants on acceptability and utility |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative comments of participants on acceptability and utility. |  | 2 months | 
| Number of medication days per month |  | 2 months |
Evaluating the AMH Levels During Natural Cycle

Study Overview
=================
Brief Summary
-----------------
To describe AMH serum levels dynamics during natural cycle using an automated assay.

Detailed Description
-----------------
The potential benefit would be using an automated assay for AMH, the dynamics of serum levels during the natural cycle and to check the inter-cycle variations. Because of the many clinical decisions that are based on AMH levels alone the results of this study could bring reassurance to the continuous use of AMH in daily practice. More importantly, no studies to date have been performed on the newer automated assays evaluating variability of AMH levels.

Official Title
-----------------
Anti-Mullerian Hormone Dynamics During Natural Cycle Using Automated Assay

Conditions
-----------------
Anti-Mullerian Hormone Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with written informed consent. Women between ≥ 18 and ≤ 37 years of age. BMI between 18 and 28. Normal physical examination and pelvic exam. Exclusion Criteria: Pregnancy. Breastfeeding. History of any disease/iatrogenic intervention which could have had an impact on the ovarian reserve (e.g. ovarian surgery, chemotherapy, radiation of the pelvis, endometriosis) Intake of OCP for the two last menstrual cycles.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 37 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AMH serum levels dynamic | In order to describe each hormone and its dynamics, will determine mean and standard deviations in each time and it will be represented with boxplot figures. Moreover,the investigator will define polynomial interpolation for dynamic values and each hormone will be represented with mean polynomial interpolation and variance band | 9months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inter-cycle AMH variations | inter-cycle variability of AMH across two cycles is concluded independently that AMH varies a little between cycles. | 9months |